

Prestige Consumer Healthcare Inc. (PBH)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001295947

Prestige Consumer Healthcare Inc. PBH; healthcare	
Grade	C/D A B C D E on the C/D boundary of 371 graded peers percentile 58.4; sampling error 2.5 points; lower is stronger
Rank	217 of 371
Profitability	C percentile 51.3
Solvency	C percentile 46.7
Growth and financing	C percentile 54.3
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$3.5B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	12 of 14
Graded from	filings received through May 14, 2026 148 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$47.85 2026-10-08; market equity \$2.3B
Price used in grade	None



C/D, the tortoise

on the C/D boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from May 21, 2025, B/C from Mar 21, 2026, C from Apr 21, 2026, C/D from May 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received May 14, 2026

- Major Brands" of this Annual Report on Form 10-K for information regarding market share. We compete for consumers' attention based on a number of factors, including brand recognition, product quality, performance, value to consumers, price and product availability at the retail level. Advertising, marketing, merchandising and packaging and the timing of new product introductions and line extensions also have a significant impact on consumer buying decisions and, as a result, on our market share and our sales. Our

markets are highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 51.3						
Gross profitability		17.0%	32.2%	67.4	372	2026-03-31
Return on invested capital		8.2%	9.3%	52.1	74	2026-03-31
Accruals ratio		(2.0%)	(6.6%)	76.5	811	2026-03-31
Gross margin stability, five years		0.8 pts	2.8 pts	9.1	243	2026-03-31
Solvency, sleeve percentile 46.7						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		4.04	(0.31)	21.6	756	2026-03-31
Net debt to EBITDA		2.73x	1.82x	67.6	75	2026-03-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2025-03-31; latest annual assets end 2026-03-31
Current ratio		3.57x	2.96x	51.1	839	2026-03-31
Growth and financing, sleeve percentile 54.3						
Revenue growth, three-year compound		(1.2%)	10.0%	74.4	415	2026-03-31
Free cash flow growth, three-year compound		3.6%	10.9%	63.2	96	2026-03-31
Reinvestment rate		(22.4%)	37.1%	80.6	104	2026-03-31
Asset growth, three years		1.4%	2.1%	48.6	704	2026-03-31
Net share issuance, one year		(4.1%)	2.5%	4.7	634	2026-05-12

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
212	Aquestive Therapeutics, Inc. (AQST)	57.0	C	
213	Tango Therapeutics, Inc. (TNGX)	57.3	C	dilution
214	Cryo Cell International Inc. (CCEL)	57.6	C/D	
215	electroCore, Inc. (ECOR)	57.8	C/D	
216	Rocket Pharmaceuticals, Inc. (RCKT)	58.1	C/D	degenerate inputs
217	Prestige Consumer Healthcare Inc. (PBH) <	58.4	C/D	
218	Becton Dickinson & Co. (BDX)	58.6	C/D	

219	Option Care Health, Inc. (OPCH)	58.9	C/D	
220	Cryoport, Inc. (CYRX)	59.2	C/D	late filer
221	GeneDx Holdings Corp. (WGS)	59.5	C/D	fortress
				balance sheet
222	Trulieve Cannabis Corp. (TRLV)	59.7	C/D	fortress
				balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(17.0%)	8.0%	32
Distance from 52-week high	(31.8%)	(31.4%)	49
EBIT to enterprise value	9.8%	(1.5%)	91
Free cash flow yield	10.9%	(1.0%)	91
Book value to price	0.85	0.28	82
Sales to price	0.48	0.31	65
Composite equity issuance, five years	(5.2%)	20.3%	20
Relative strength against the sector, log excess return	(0.40)	(0.14)	32

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2026-03-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$89.1M
Operating cash flow, four quarters	\$249.4M
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$24.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$595.6M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
2	assets	us-gaap:Assets	\$3.5B	2026-03-31	2026-05-14	10-K	0001295947-26-000016
3	operating income	us-gaap:OperatingIncomeLoss	\$309.4M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$257.5M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$67.2M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
6	total debt	us-gaap:LongTermDebt	\$994.0M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
7	book equity	us-gaap:StockholdersEquity	\$1.9B	2026-03-31	2026-05-14	10-K	0001295947-26-000016
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$63.9M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
9	total debt	us-gaap:LongTermDebt	\$992.4M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
10	book equity	us-gaap:StockholdersEquity	\$1.8B	2025-03-31	2026-05-14	10-K	0001295947-26-000016
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$97.9M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
12	net income	us-gaap:NetIncomeLoss	\$190.3M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$257.6M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
14	assets	us-gaap:Assets	\$3.4B	2025-03-31	2026-05-14	10-K	0001295947-26-000016
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2026-03-31	2026-05-14	10-K	0001295947-26-000016
16	gross profit	us-gaap:GrossProfit	\$634.5M	2025-03-31	2026-05-14	10-K	0001295947-26-000016

17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2025-03-31	2026-05-14	10-K	0001295947-26-000016
18	gross profit	us-gaap:GrossProfit	\$624.4M	2024-03-31	2026-05-14	10-K	0001295947-26-000016
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2024-03-31	2026-05-14	10-K	0001295947-26-000016
20	gross profit	us-gaap:GrossProfit	\$625.3M	2023-03-31	2025-05-09	10-K	0001295947-25-000017
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2023-03-31	2025-05-09	10-K	0001295947-25-000017
22	gross profit	us-gaap:GrossProfit	\$620.6M	2022-03-31	2024-05-15	10-K	0001295947-24-000017
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1B	2022-03-31	2024-05-15	10-K	0001295947-24-000017
24	current assets	us-gaap:AssetsCurrent	\$431.5M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
25	current liabilities	us-gaap:LiabilitiesCurrent	\$120.9M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$1.7B	2026-03-31	2026-05-14	10-K	0001295947-26-000016
27	liabilities	us-gaap:Liabilities	\$1.6B	2026-03-31	2026-05-14	10-K	0001295947-26-000016
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$31.3M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
29	operating income	us-gaap:OperatingIncomeLoss	\$336.8M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
30	interest expense	us-gaap:InterestExpense	\$1.8M	2025-03-31	2025-05-09	10-K	0001295947-25-000017
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$11.2M	2026-03-31	2026-05-14	10-K	0001295947-26-000016
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$251.5M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.2M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$248.9M	2024-03-31	2026-05-14	10-K	0001295947-26-000016
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$9.6M	2024-03-31	2026-05-14	10-K	0001295947-26-000016
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$229.7M	2023-03-31	2025-05-09	10-K	0001295947-25-000017
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$7.8M	2023-03-31	2025-05-09	10-K	0001295947-25-000017
38	current assets	us-gaap:AssetsCurrent	\$448.3M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
39	current liabilities	us-gaap:LiabilitiesCurrent	\$106.6M	2025-03-31	2026-05-14	10-K	0001295947-26-000016
40	assets	us-gaap:Assets	\$3.3B	2024-03-31	2025-05-09	10-K	0001295947-25-000017
41	assets	us-gaap:Assets	\$3.4B	2023-03-31	2024-05-15	10-K	0001295947-24-000017
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	47,372,166	2026-05-12	2026-05-14	10-K	0001295947-26-000016
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,414,707	2025-05-01	2025-05-09	10-K	0001295947-25-000017